Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Pennsylvania was posted on September 24, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Research to Cure & Prevent T1 Juvenile Diabetes

Closed
RFA67-205State & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

about 5 hours ago

DEADLINE

N/A
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (FDABAA-27-00123) solicits basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grants Services, this solicitation is open to all responsible sources, including small businesses and academic institutions. The program focuses on 22 priority research areas, with recent updates adding specific interests in human tooth enamel evaluation techniques for anticaries dentifrice products and the adoption of Super Intelligence terminology in tobacco and nicotine research per Executive Order 14434. Interested parties must follow a two-tiered submission process consisting of a three-page concept paper and a comprehensive full proposal, which includes a technical volume limited to 50 pages and a detailed cost proposal. All applications must be submitted as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. A virtual BAA Day is scheduled for December 8, 2026, to provide guidance on the application process and FDA priorities. Awards are based on the overall best value to the government, evaluated through a high-level relevance review followed by a technical review by subject matter experts. Successful offerors must comply with Good Manufacturing Practice Regulations (21 CFR Parts 210-211) and other relevant biological or diagnostic standards. Additionally, proposals exceeding $900,000 from non-small businesses require a Small Business Subcontracting Plan. Contractors must also warrant the absence of organizational conflicts of interest and adhere to strict data disclosure and privacy regulations.
FDA Office Of Acq Grant Svcs

POSTED

1 day ago

DEADLINE

in 2 months
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.
Tribal & Science Division Water

POSTED

4 days ago

DEADLINE

in 13 days
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

4 days ago

DEADLINE

in 13 days
NAICS: 541714
New
Federal
Laguna Industry Day
Solicitation # DARPA-SN-27-18
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is hosting a virtual Industry Day on December 9, 2026, for the Laguna program under Special Notice DARPA-SN-27-18. The program's primary objective is to develop and demonstrate integrated manufacturing approaches that convert abundant domestic feedstocks, such as sugars, ethylene, and BTX, into application-ready specialty chemical formulations. By minimizing intermediate processing steps and separations, the initiative seeks to reduce reliance on vulnerable foreign supply chains. The anticipated 36-month effort is divided into two technical areas: Make and Formulate, which focuses on developing defense-relevant specialty products from U.S. raw materials, and Model, which aims to create predictive tools to optimize the relationship between feedstocks, synthesis, and final product performance. This notice is issued for information and program planning purposes and does not constitute a formal solicitation for proposals. Interested parties must register for the Industry Day event by December 2, 2026. The program requires that resulting products meet or exceed the performance of current military materials, with deliverables including technoeconomic analyses, life cycle assessments, and commercialization strategy plans. Technical and administrative inquiries are managed by Dr. William Mounfield and can be directed to [email hidden]. A draft program solicitation is expected to be released on sam.gov prior to the Industry Day event.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 15 days

AI Contract Overview

Show more

The contract pertains to a research initiative aimed at curing and preventing Type 1 Juvenile Diabetes, with a focus on restoring normal blood sugar levels and addressing related complications. Funded by the Pennsylvania Department of Health under the RFA67-205 solicitation, the project seeks proposals from eligible Pennsylvania-based researchers, with a budget range of $500,000 to $2,000,000. The solicitation emphasizes ethical compliance, requiring certifications for human subjects protection, stem cell research, recombinant DNA work, and animal care, all of which must be submitted and approved prior to project initiation. Applicants are also required to adhere to federal standards, including NIH guidelines and NIH-mandated ethical standards, as evidenced by signed memoranda of understanding. The application process involves submitting a Letter of Intent by November 3, 2025, and a full proposal by November 24, 2025, via a designated SharePoint portal. The process includes comprehensive documentation such as detailed research proposals, budget summaries, and certifications related to lobbying, ethical standards, and research containment. The contract emphasizes transparency, regulatory compliance, and ethical conduct, with specific instructions on proposal formatting and confidentiality. Successful proposals will contribute to advancing health research in Pennsylvania, with the potential to attract further funding and support efforts to develop effective prevention and treatment strategies for Juvenile Diabetes.

Documents

10
DOCX, High priority: read this first3 pages · presolicitation
High
PDF, High priority: read this first83 pages · rfp
High
DOC, High priority: read this first2 pages · presolicitation
High
XLS, Low priority9 pages · other
Low
DOC, Low priority1 page · other
Low
DOCX, Low priority1 page · other
Low
DOCX, Low priority1 page · other
Low
DOCX, Low priority1 page · other
Low
DOCX, Low priority1 page · other
Low
DOCX, Low priority32 pages · baa
Low

Read all 10 documents

Every page of every file, in your free workspace.

Read the documents

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

This one is closed. Find the next one like it.

Open contracts like this one, right now:

  • Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)Open now
  • Clinical Research Site Operations and Participant ManagementOpen now, due in 9 days
See open contracts like this

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyPennsylvania → Department of Health
Contacts1 person available
OfficeN/A

Full Description

Show more
Research related to preventing T1 (Juvenile)Diabetes, restoring normal blood sugar levels and preventing and reversing complications of T1 (Juvenile) Diabetes.All Bids must arrive prior to the Bid opening date and time to be considered and become property of the Commonwealth once submitted.

More opportunities from Pennsylvania → Department of Health

Same awarding agency

NAICS: 541715
SLED
Spinal Cord Injury Research Grant
Solicitation # 67-211
The Pennsylvania Department of Health issued Request for Applications RFA 67-211 to fund innovative biomedical, clinical, and health services research aimed at improving treatments and rehabilitation for individuals with spinal cord injuries. Established under Act 126 of 2018, the program offers three funding tiers: Pilot Project Grants, Standard Research Grants with a maximum budget of 300,000 dollars, and Clinical/Translational Research Grants with a maximum budget of 500,000 dollars. A critical requirement is that at least 50 percent of requested funds must be dedicated to clinical or health services research. The anticipated period of performance runs from July 1, 2027, to June 30, 2031, with a maximum total term not to exceed four years. Applicants must submit a non-binding Letter of Intent by November 9, 2026, followed by a final application by December 10, 2026. The selection process involves a two-stage review by a Department Review Committee based on scientific need, method, research design, facility adequacy, and personnel qualifications. Mandatory submissions include a signed cover page, a detailed research proposal, a budget in Excel format, and various certifications regarding worker protection, ethical standards, and the protection of human and animal subjects. All research involving human subjects requires Institutional Review Board approval, and grantees must adhere to National Institutes of Health ethical standards and Pennsylvania state labor laws.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in 23 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS